The company said expectations of a better second half of the current financial year (H2FY25) is based on facility ramp up, delivery of late-phase NCE projects, and Ebitda margins improvement
Eris Lifesciences, BLS International and Five-Star Business are the other 3 smallcap stocks that look favourably placed on the technical charts in an otherwise weak market.
Individually, shares of Laurus Labs rose up to 5.55 per cent at Rs 517.90 per share, Akums Drugs and Pharmaceuticals shares locked in 5 per cent upper circuit at Rs 910.55 a piece
Stocks with long buildup in August series: Key levels to track on Voltas, Naukri and Laurus Labs as these stocks could potentially gain up to 9 per cent from present levels.
5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.
According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year
Goldman Sachs attributes India's underpenetrated CDMO and CRO market to smaller capacities, lack of Innovation with little collaboration between Industry and academia
Company reported lower-than-expected revenue after missing target in key segment
Despite these cuts, the brokerage maintains a buy rating on the stock
Laurus Synthesis Private Limited has been issued a Form 483 with five observations and the company plans to address the observations within stipulated timelines.
Stocks to Watch on December 13, 2023: PE giant Bain Capital is likely to sell up to 1.1 per cent stake in Axis Bank via a block deal, reported Moneycontrol
Rivals Sun Pharma's Dadra facility and Torrent Pharmaceuticals Ltd's oncology unit are also undergoing FDA inspections
The acquisition was made through a secondary purchase from the promoter group shareholders of Laurus Bio on November 20, 2023
Barring, Pfizer, Gland Pharma, and Laurus Labs, all other constituents of Nifty Pharm Index trade over the 200-day simple moving average (SMA),
Lower sales, operational deleverage and elevated expenses were listed as reasons for subdued financial performance
Laurus Labs delivered operationally in-line performance, led by healthy traction in CDMO-Synthesis/Non-ARV API segment
India's Laurus Labs Ltd reported a 32.1% rise in third-quarter profit on Monday, boosted by strong demand in its businesses that make chemicals and other ingredients used in medicines
According to the technical analyst from Anand Rathi, Laurus Labs can rally to Rs 400; while RateGain can jump to Rs 330.
One other employee is undergoing treatment in a hospital after the incident that occurred on Monday evening
Laurus has witnessed severe pricing pressure and lower volumes in its ARV formulations portfolio for five quarters now, resulting in significant pressure on core margins, say analyst.